Go to:
Logótipo
Você está em: Start > Publications > View > Oligomerization capacity of two arylsulfatase A mutants: C300F and P425T
Map of Premises
Principal
Publication

Oligomerization capacity of two arylsulfatase A mutants: C300F and P425T

Title
Oligomerization capacity of two arylsulfatase A mutants: C300F and P425T
Type
Article in International Scientific Journal
Year
2003
Authors
marcao, a
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
azevedo, je
(Author)
ICBAS
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
gieselmann, v
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
miranda, mcs
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 306
Pages: 293-297
ISSN: 0006-291X
Publisher: Elsevier
Other information
Authenticus ID: P-000-G8P
Abstract (EN): Arylsulfatase A (ARSA) is a lysosomal enzyme implicated in most cases of metachromatic leukodystrophy (MLD). The quaternary structure of ARSA is pH-dependent: at neutral pH, ARSA is a. homodimeric protein; at lysosomal (acidic) pH, ARSA is homo-octameric. This dimer-octamer transition seems to be of major importance for the stability of the enzyme in the lysosomal milieu. Sedimentation analysis was used to study the oligomerization capacity of C300F and P425T-substituted ARSA, two MLD-associated forms of the enzyme displaying reduced lysosomal half-lives. P425T-ARSA displays a modest reduction in its octamerization capacity. In contrast, the C300F mutation strongly interferes with the octamerization process of ARSA but not with its dimerization capacity. Interestingly, a major fraction of dimeric ARSA-C300F is composed of covalently linked ARSA molecules, through a thiol-cleavable bond that probably involves Cys414 residues from each monomer. Our data support the notion that the reduced lysosomal half-life of some mutated forms of ARSA is related to deficient octamerization. (C) 2003 Elsevier Science (USA). All rights reserved.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 5
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

Human carbamoyl phosphate synthetase I (CPSI): Insights on the structural role of the unknown function domains (2012)
Another Publication in an International Scientific Journal
Monica Lopes Marques; Gilberto Igrejas; Antonio Amorim; Luisa Azevedo
Unusual self-association properties of transthyretin Y114C related to familial amyloidotic polyneuropathy: Effects on detection and quantification (1999)
Article in International Scientific Journal
Ando, Y; Almeida, MD; Ohlsson, PI; Ando, E; Negi, A; Suhr, O; Terazaki, H; Obayashi, K; Ando, M; Saraiva, MJM
Transcriptional regulation of the human mitochondrial peptide deformylase (PDF) (2012)
Article in International Scientific Journal
Isabel Pereira Castro; Luis Teixeira da Costa; Antonio Amorim; Luisa Azevedo
TP53 and P21 polymorphisms: Response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer (2006)
Article in International Scientific Journal
Santos, AM; Sousa, H; Portela, C; Pereira, D; Pinto, D; Catarino, R; Rodrigues, C; Araujo, AP; Lopes, C; Medeiros, R
The influence of HER2 genotypes as molecular markers in ovarian cancer outcome (2005)
Article in International Scientific Journal
Pinto, D; Pereira, D; Portela, C; da Silva, JL; Carlos, LA; Medeiros, R

See all (23)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Medicina Dentária da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z  I Guest Book
Page created on: 2025-06-25 at 00:43:55 | Acceptable Use Policy | Data Protection Policy | Complaint Portal